Critical Survey: Cardio Diagnostics (NASDAQ:CDIO) and Lucira Health (NASDAQ:LHDX)

Cardio Diagnostics (NASDAQ:CDIOGet Rating) and Lucira Health (NASDAQ:LHDXGet Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Analyst Ratings

This is a summary of current ratings for Cardio Diagnostics and Lucira Health, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cardio Diagnostics 0 0 0 0 N/A
Lucira Health 0 0 1 0 3.00

Cardio Diagnostics presently has a consensus target price of $8.00, suggesting a potential upside of 614.29%. Given Cardio Diagnostics’ higher possible upside, equities research analysts plainly believe Cardio Diagnostics is more favorable than Lucira Health.


This table compares Cardio Diagnostics and Lucira Health’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cardio Diagnostics N/A N/A N/A
Lucira Health -67.54% -13.55% -8.47%

Institutional and Insider Ownership

77.3% of Cardio Diagnostics shares are owned by institutional investors. Comparatively, 57.0% of Lucira Health shares are owned by institutional investors. 30.4% of Lucira Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Cardio Diagnostics and Lucira Health’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cardio Diagnostics N/A N/A -$140,000.00 N/A N/A
Lucira Health $93.06 million 0.14 -$64.83 million ($3.58) -0.09

Cardio Diagnostics has higher earnings, but lower revenue than Lucira Health.


Cardio Diagnostics beats Lucira Health on 6 of the 9 factors compared between the two stocks.

About Cardio Diagnostics

(Get Rating)

Cardio Diagnostics Holdings, Inc., a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois.

About Lucira Health

(Get Rating)

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.

Receive News & Ratings for Cardio Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardio Diagnostics and related companies with's FREE daily email newsletter.